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Abstract 
 
Less than 5% of patients develop Complex Regional Pain Syndrome (CRPS) after trauma, 
mostly after fractures. It is a painful syndrome characterized by a variety of clinical features 
including classical signs of inflammation and it can become chronical if not cured in the first few 
months. Likely, a number of pathophysiological mechanisms play a role in CRPS. The 
involvement of neuropeptides and anti-inflammatory lipid mediators has been suggested. Here, 
mass spectrometry (MS) was used to investigate these molecules in skin biopsies and serum 
with the aim of correlating their concentration with clinical parameters. High-end and in 
particular nanoscale MS identified peptides as well as fatty acids at the low fmol level. However, 
it also showed little tolerance for the chemical background so that a more robust capillary 
chromatography approach was preferentially used. Serum protease activity with a focus on 
angiotensin converting enzyme (ACE) was studied. Bradykinin (BK) was rapidly degraded to 
BK1-8 and BK1-5. The formation of lower BK1-5 levels was indicated in agreement with the 
hypothesis of reduced ACE-activity in CRPS. 
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Introduction 
 
CRPS is a severe and often disabling syndrome, which develops after trauma in ~5% of all 
cases; most often after distal radius fractures [1]. CRPS is characterized by a variety of clinical 
features including spontaneous pain and hyperalgesia [2]. Increased neuropeptide release from 
peripheral nociceptors has been suggested as a possible pathophysiological mechanism 
triggering the symptoms [2]. Bradykinin (BK, Figure 1), for instance, participates in inflammatory 
processes, producing classical symptoms of inflammation such as redness, heat, swelling, and 
pain [3]. It was increased in blood samples from CRPS patients [4] and its decreased 
degradation by angiotensin converting enzyme (ACE) was thought to be involved in the 
pathophysiological mechanism [5, 6]. Other peptides of interest were calcitonin gene-related 
peptide (CGRP), substance P (SP), endothelin I (ET-1) and vasoactive intestinal peptide (VIP) 
(Figure 1) [7]. Moreover, resolvins (Figure 2), endogenous anti-inflammatory lipid mediators, are 
generated during the resolution phase of acute inflammation and emerging evidence points to a 
potent anti-hyperalgesic role in inflammatory pain [8, 9]. A detailed overview for these pro- and 
anti-inflammatory signal molecules including cytokines and peptidases and their analytical 
detection is given in [10]. 
Here, mass spectrometry (MS)-based investigations of both peptide and lipid marker 
substances in inflamed tissue (skin) and serum of patients vs. controls are described. The 
report is divided by task: 1) Extraction of the substances to be investigated from the respective 
biological matrix, 2) Analysis of resolvins, and 3) Detection of neuropeptides and monitoring of 
protease activity. 
 
  Bradykinin (BK) 
RPPGFSPFR 
 
Substance P (SP) 
RPKPQQFFGLM-NH2 
 
Neurotensin (NT) 
pQLYENKPRRPYIL 
 
Vasoactive intestinal peptide (VIP) / VIP 1-12 
HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 
 
Endothelin 1 (ET-1) / ET-1 1-9 
CSCSSLMDKECVYFCHLDIIW 
 
Calcitonin gene-related peptide (CGRP) / CGRP 25-35 
ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 
 
β-nerve growth factor (NGF) / β-NGF 1-9  
SSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRD 
PNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA 
 
Figure 1: Increased neuropeptide release from peripheral nociceptors may be a possible 
pathophysiological mechanism triggering CRPS symptoms. Full sequences for peptides of interest are 
shown with target sequences marked.  
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Figure 2: Resolvins D1 and D2 
 
 
 
 
 
Part 1  
Extraction of marker substances from patient material 
 
Biochemical indicators for an increased post-traumatic inflammation or an insufficient inhibition 
of the inflammation in CRPS should be preferentially studied at the location of the symptoms, 
namely in skin biopsies. Two skin biopsies are typically the maximum which can be expected 
from one patient at a time and for many tests such as zymography one is completely used up. 
Thus, we aimed for the double use of one biopsy for both the extraction of fatty acids and of 
peptides in order to save patient material. We first extracted the lipids with organic solvent and 
subsequently isolated the peptides (Figure 1.1).  
 
 
Figure 1.1:  
Workflow for the analysis of lipid and 
peptide marker molecules from skin 
biopsies. In general, it was applied to 
serum as well. 
 
 
 
 
 
 
 
Analyses were conducted following the general principle shown in Figure 1.2. First, the 
response of the instruments was determined with respect to sensitivity and accuracy using 
commercially available standards. In the second step, these standard substances were spiked 
to control material at defined concentrations in order to study their recovery and to find 
unexpected difficulties introduced by the biological material. Finally, the method was applied to 
patient samples. 
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Method development with 
commercial standards 
Method application to control 
skin using spiked in standards 
Analysis of patient material 
 
 
 
 
 
 
Figure 1.2: Protocol steps for 
biomarker analysis 
 
 
Experiments 
 
During the experiments, the declaration of Helsinki in its revised form of Oktober 1983, Venedig, 
was observed. The Ethics Commission of Landesärztekammer Mainz has allowed the clinical 
investigation and the collection of skin biopsies (No. 837.050.04 (4208), LÄK Rheinland-Pfalz). 
Inclusion criteria met the diagnostic criteria of the IASP (International Association for the Study 
of Pain; age > 18 years). Written informed consent was obtained from all subjects.  
Skin biopsies were collected intra-cutaneously after local anasthesia with 1 ml lidocain 2% at 
the most affected site and at the corresponding site of the contralateral extremity. Healthy 
control persons donated biopsies from the same sites. Breast skin tissue was used for method 
development. Subcutaneous fat was removed from the skin sample. Samples were frozen in 
liquid nitrogen and sent on dry ice from Mainz to Münster. They were stored at -80°C until 
further use.  
Patient blood was drawn into EDTA-free S-Monovette® (Sarstedt). In case of the determination 
of endogenous BK, protease inhibitor-containing vials could be used in contrast to 
measurement of protase activity. In the latter case also the use of anticoagulants such as EDTA 
should be avoided as it is a Zn chelator and competes for Zn with ACE [11-12]. Following 
transport and handling at room temperature, samples were centrifuged and aliquoted for 
storage at -80°C. They were subsequently treated as illustrated in Figure 1.3. Several traditional 
methods for lipid extraction such as those of Folch [13] and Bligh and Dyer [14] have been 
tested (see also [15]). A major reason to ultimately perform resolvin extraction using the 
optimized protocol of Matyash et al. [16] and Giera et al. [17] was the fact that handling was 
much improved in the methyl-tert-butylether (MTBE) method as the organic layer was well 
accessible at the top (Figure 1.4).  
Peptides were purified as shown in Figure 1.5. The larger peptides such as CGRP, VIP and 
ET -1 were tryptically digested to generate shorter target peptides for gas phase fragmentation 
analysis. This measure improved peptide recovery and identification confidence by matching 
experimental peptide fragment ions with MS/MS data obtained from the commercial standards.  
For the extraction of peptides, in particular BK, from serum or plasma, we followed 
recommendations by Aristoteli et al. [18]. The authors had compared several methods and 
found that both acetonitrile (ACN)-extraction (ACN:serum 2:1 v/v; 10:1 v/v) and 
ultracentrifugation showed best recoveries for low molecular weight peptides. In our case, the 
first method worked best when tested for BK (Figure 1.6). Thus, ACN was added to the serum 
at a ratio of 2:1 v/v and incubated for 30 min at room temperature at a shaker (1000 rpm). 
Subsequently, the sample was centrifuged for 10 min at 12000 x g. The supernatant was 
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lyophilised and redissolved in 10 µl 95:5 v/v H2O:ACN, 0.1% formic acid (FA). Extracted 
peptides from skin biopsies were dissolved in the same way.  
 
 
 
 
 
Figure 1.3: Treatment of skin 
biopsies for lipid extraction 
optimized after Matyash [16]. 
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Figure 1.4: Comparison of lipid extraction methods. The advantage of the MTBE method is the 
convenient separation of the organic (org.) layer to the top. [16, 17] 
 
MS experiments were performed using reversed-phase liquid chromatography (RP-LC) coupled 
to different types of mass spectrometers. Best sensitivity was achieved with nanoLC-MS/MS 
using nanoAcquity coupled to Q-TOF Premier or M-Class coupled to Synapt G2 Si (all from 
Waters Corp.). However, despite additional filtering steps, samples derived from these complex 
biological matrices tended to build up material in the nanoLC-system resulting in frequent 
clogging and instrument downtime. Therefore, a more robust capillary LC coupled to an iontrap 
instrument (Poroshell 120 EC-C18, Agilent HP1100, Bruker Esquire 3000) was used for most 
experiments. For measurement on the iontrap 5 µl were injected. AutoMS/MS on the doubly 
charged ion was used (scan range m/z 100-1100). Commercial sources for chemicals and 
material are given in Table 1.1. 
 
 
 
Figure 1.5: Peptides were isolated from the 
aqueous phase after lipid extraction. 
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Figure 1.6: MS/MS spectra for BK (50 pmol) recovery from 100 µl serum using ACN 
precipitation (see text and [18]). Dried extracts were redissolved in 10 µl 5% ACN containing 
0.1% FA. LC-MS/MS was carried out with Esquire3000 on the doubly-charged BK ion (2 µl 
injection; note zoom area in spectra). 
 
 
Table 1.1: Sources of neuropeptides, chemicals and material 
Chemicals Degree of purity CAS-number Manufacturer 
Bradykinin acetate salt ≥98 % 6846-03-3  
 
 
 
 
 
SIGMA-ALDRICH 
 
Substance P acetate salt hydrate ≥95 % 137348-11-9 
Neurotensin ≥90 % 58889-67-1 
Vasoactive intestinal peptide ≥95 % 40077-57-4 
Endothelin 1 ≥97 % 117399-94-7 
Calcitonin gene-related peptide ≥95 % 90954-53-3 
β-nerve growth factor ≥97 % not specified 
Acetonitrilchr. ≥ 99,9 % 75-05-8 
Waterchr for HPLC 7732-18-5 
Methanolchr. ≥ 99,9 % 67-56-1 
Methyl tert-butyl ether ≥ 99,8 % 1634-04-4 
Dithiothreitol ≥ 99,0 % 3483-12-3 FLUKA 
Iodoacetamide ≥ 99,0 % 144-48-9 SIGMA 
Trypsin/Lys-C Mass Spec Grade not specified Promega 
Resolvin D1 ≥ 95 % 872993-05-0 Cayman 
Chemical Resolvin D2 ≥ 95 % 810668-37-2 
    
Material Product number   
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Ziptip® µC-18 Pipette Tips ZTC18M690  Millipore 
Oasis® HLB 1cc 186000383  Waters Corp. 
S-Monovette® 02.1726.01  Sarstedt 
Part 2  
Resolvin MS-based analysis  
 
As shown by other authors earlier, fatty acids can be detected with reversed phase 
chromatography coupled to MS, preferentially in negative ion mode [19-22]. Using positive ion 
mode, we demonstrated a detection limit in the low fmol range (Figure 2.1) even from methanol 
solutions; 0.1-0.3 ng fatty acid were sufficient for analysis. In negative ion mode, sensitivity was 
even better (low fmol / high amol range; shown for 15 pg in Figure 2.2). However, a limitation of 
the nanoLC technologies was their little tolerance towards chemical background of the sample 
so that the more robust capLC was alternatively used (Figure 2.3, 2.4).  
 
 
 
Figure 2.1: Fragmentation analysis of RvD2 (500 fmol on-column) in positive ion mode using Q-
TOF Premier and nanoAcquity (top trace MS scan). Water losses are indicated by arrows. The 
sodiated ion was more abundant than the protonated ion, but did not provide very specific 
MS/MS data (bottom trace). Therefore, for MS/MS the protonated ion which has lost one water 
molecule (m/z 359.2; middle trace) was used.  
  
MERCATOR J Biomol Anal (2017) 1:1       9 
 
 
 
 
 
Figure 2.2: Fragmentation 
analysis of RvD1/2 (50 and 
250 fmol on-column) in 
negative ion mode using 
Synapt G2 Si with iKey and 
MClass (Waters Corp.; 
11 min runs, peptide BEH 
C18 130 Å 1.7 µm 150 µm x 
50 mm iKey). a) Base peak 
chromatogram of MS and 
MS/MS (left) and MS peak for 
one scan (right). 
 
 
 
b) Corresponding MS/MS 
data for 3 scans. Major 
fragment ions are labeled. 
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Figure 2.3:  Esquire3000 MS and MS/MS spectra of RvD1. Top: MS spectrum of 100 pmol 
RvD1 spiked to skin biopsy; the extract was dissolved in 10 µl and 9 µl were injected for 
measurement. Bottom: two MS/MS spectra of precursor ion m/z 399.9, upper RvD1 recovered 
from biopsy, lower RvD1 standard (5 pmol on-column).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: UV-chromatogram at 290 nm (HP1100) for 
RvD1 (19 min) and RvD2 (14.5 min) spiked to control skin 
and recovered at ~90 pmol.  
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Resolvin injection inhibits spontaneous pain, heat and mechanical hypersensitivity evoked by 
capsaicin and tumor necrosis factor (TNF)-α [23]. The detection of endogenous resolvins in 
body fluids or tissue is thus of interest but also a matter of debate. We could recover spiked 
resolvins from skin and detect it using LC/iontrap MS at pmol sensitivity (Figure 2.3; the 
instrumental detection limit of this set-up was 1 pmol resolvin standard on-column, recovery of 
10 pmol resolvin spiked to water/ethanol 9:1 v/v was possible). For serum; spectra were 
obtained for 1/5 of the extract recovered from 100 pmol resolvin spiked to 100 µl serum. This 
volume was chosen as a compromise – extraction from more serum volume increased the 
danger of matrix accumulation on-column with low-flow chromatography.  
So far, we have not been successful in finding endogenous resolvins neither in biopsies nor in 
serum even when using more sensitive analytical instrumentation. Neither did other authors 
working with state-of-the-art MS equipment [24-25] even when supplying fish oil containing 
nutritional supplements to probands. On the other hand, in an excellent quantitative study by 
Colas et al. [26] resolvins were measured in pooled serum of healthy volunteers at 
concentrations of 31 ± 7 pg/ml (RvD1) and 41 ± 14 pg/ml (RvD2) and in pooled human plasma 
at concentration of 2.6 ± 0.1 pgl/ml (RvD1) [26]. The detected amounts however corresponded 
to the lower limit of the calibration curve or were even outside it. The multi-reaction monitoring 
approach was chosen to guarantee specificity but may have been hampered by co-isolated 
peaks. We have seen a lot of overlapping ions in lipid spectra as masses are often only 2 Da 
apart (unsaturation). MS/MS spectra were therefore populated by fragment ions derived from 
several precursors. We thus concluded that additional preparation and prefractionation of serum 
lipids would be necessary to circumvent this effect. In any case, MS/MS fragmentation of fatty 
acids is characterized by water losses and few if any characteristic ions. As Figure 2.2b 
illustrates, RvD1 and RvD2 can hardly be distinguished apart from the ion at m/z 175 originating 
from the different location of the OH-groups. Moreover, variation in instrumental design and 
collision processes may cause a shift in fragment ion intensities which could be the reason for 
the differences in our MS/MS data and those shown by Colas et al. [26]. Other authors also 
claimed resolvin detection in blood but did not show experimental data [27, 28]. Murphy [29] 
elaborates in an interesting comment that there are inherent challenges in lipid analysis and that 
the results and conclusions which have been reached so far “are at odds with each other”. 
Working at the limit of detection, published data do not seem sufficiently robust so far.  
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Part 3 
Neuropeptide MS-based analysis 
 
Protease activity can be measured using established gelatinase activity assays and 
zymography [30, 31]. Those methods work quantitatively, but they require significant amounts of 
material. MS, in contrast, can detect peptide signals in the low fmol /high amol range and it 
offers the possibility for multiplexing. First results have been achieved investigating 
adrenocorticotropin und α-melanocyte-stimulating hormon in skin and skin cells in the context of 
protease activity (neprylisin, ACE [32, 33]. Although the low fmol MS detection limits for 
peptides are in general highly promising for biomarker monitoring, there are unexpected 
analytical challenges. SP and ET-1, for instance, showed fast adsorption to the vessel wall 
(glass, 5 min) which limited quantification as an LC injection cycle was as long as 3 min 
depending on the set-up. The negative potential of glass surfaces offers optimal conditions for 
electrostatic interactions wih the positive charge of a peptide [34, 35]. It would be possible to 
affect the electrostatic interaction with the addition of salts [36, 37], but that is not an option in 
the RP-LC coupling. The recovery of ET-1 and VIP was not reliable even when tryptic digestion 
was used for the creation of target peptides. 
Disulfide formation may be partially responsible 
for this observation. The VIP target peptide was 
susceptible to in source fragmentation in the 
mass spectrometer preventing proper 
quantitation. Thus, we developed a MS-
independent labeling method  (either 
dabsylation or fluorescent labeling) to measure 
peptides resisting MS-based quantification with 
thin-layer chromatography (TLC, [38]). The LC-
MS analytical work subsequently focused on 
BK and CGRP peptide 25-35. While CGRP 
could be measured intact (Figure 3.1), digestion 
improved detection from serum via MS/MS 
target analysis. In addition, β-nerve growth 
factor (β-NGF) was analyzed, because it was 
found to sensitize pain processing [39]. β-NGF 
tryptic peptide 1-9 was targeted. Figure 3.2-3.4 
present data for peptide recovery from skin.  
 
 
 
 
 
 
Figure 3.1: MS spectrum of CGRP (1 pmol) 
measured with Q-TOF Premier. Charge states 
are labeled.  
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Figure 3.2: MS spectra of 
β-NGF1-9. a/b) Recovered 
from biopsy (100 pmol β-
NGF/biopsy), a) MS scan, 
[M+2H]2+ ion at m/z 534.4   
b) MS/MS at m/z 534,4 
c): MS/MS for trypsin-
digested standard (10 pmol 
on-column). 
 
 
 
 
 
 
 
 
 
Figure 3.3: MS spectra of 
CGRP25-35. a/b) 
Recovered from biopsy 
(100 pmol CGRP/biopsy), 
a) MS scan, [M+2H]2+ ion 
at m/z 588.8, b) MS/MS at 
m/z 588.8, c): MS/MS for 
trypsin-digested standard 
(10 pmol on-column). 
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Figure 3.4: MS spectra of 
BK1-9. a/b) Recovered 
from biopsy (10 pmol 
BK/biopsy), a) MS scan, 
[M+2H]2+ ion at m/z 530.9, 
b) MS/MS at m/z 530.9, c) 
MS/MS for BK standard 
(2 pmol on-column). 
 
 
 
 
 
 
 
 
 
 
 
Spiked peptides were recovered at the low pmol / high fmol level from both skin and plasma 
when measured with capLC-iontrap instrumentation (Figure 3.5, 3.6). However, in particular for 
CGRP and β-NGF recovery was not reliable. BK measurement appeared more promising and 
was studied in detail. Endogenous BK was detected with 103 to 104 fragment ion counts when 
purified from 1 ml plasma. It was, however, important when investigating BK to take 
precausions with respect to peptidase activity. In human blood BK is rapidly cleaved by ACE 
and carboxypeptidase N (CPN) [40, 41]. On the other hand, BK may still be formed from plasma 
kallikrein [42]. Modulation of BK signaling is largely determined by ACE which metabolizes the 
BK nonapeptide into BK1-7 heptapeptide and the BK1-5 pentapeptide [40]; degradation by 
aminopeptidase P (APP, cleaves position 1-2) and CPN (cleaves position 8-9) [41] (Figure 3.7). 
Interestingly, patients which took ACE-inhibitors when they were injured were more likely to 
develop posttraumatic CRPS  [6]. ACE is known to degrade peptides (SP, ET-1, CGRP, BK 
[43]), and inflammatory cytokines [44]), but also activates inflammatory cytokines from inactive 
precursors [30] and thus participates in the regulation of posttraumatic inflammation.  
 
MERCATOR J Biomol Anal (2017) 1:1       15 
 
 
 
 
 
 
Figure 3.5: Recovery of spiked peptides BK, CGRP25-35 and βNGF1-9 from 100 µl blood plasma. 
MS/MS spectra of a) BK1-9, 5 pmol spike, m/z 530.9, b) CGRP25-35, 50 pmol spike, m/z 588.8, 
c) βNGF1-9,100 pmol spike, m/z 534.25  
 
 
Figure 3.6: Recovery of BK spiked to 100 µl 
plasma. Detection at m/z 530.9 with iontrap. 
 
 
 
 
 
 
MERCATOR J Biomol Anal (2017) 1:1       16 
 
 
 
 
 
Figure 3.7: BK cleavage sites 
 
 
 
 
 
 
In order to study BK degradation and protease activity in sera of CRPS patients, methods were 
developed to monitor levels of spiked BK and its products. BK1-8, BK1-7 and BK1-5 were 
investigated using capillary chromatography coupled to ion trap mass spectrometry (LC-MS; 
Agilent HP1100, Bruker Esquire3000) and nano and iKeyLC coupled to high resolution MS 
(Waters MClass & Synapt G2 Si). Experiments were conducted in 2 µl serum which degraded 
50 pmol BK within 10-15 min at 37°C. Incubation was stopped by the addition of ice-cold 
acetonitrile and samples were filtered with Nanosep® Centrifugal Devices (cut off 3 kD, Pall 
Corporation; for filter tests see Figures 3.8 and 3.9) to protect low-flow chromatography set-ups. 
After lyophilisation samples were dissolved in 10 µl LC solvent A of which 5 µl were injected to 
capLC-iontrap and 1 µl to the nanoLC setup. Calibration curve and example spectra for iontrap-
MS are shown in Figures 3.10 and 3.11, for Synapt MS in Figures 3.12 and 3.13. 
 
 
Figure 3.8: Recovery of 50 pmol BK1-9, 
BK1-8 and BK1-5 standards after cut-off 
3 kDa filtration with Nanosep® Centrifugal 
Devices and Amicon®-Ultra Centrifugation 
Filters (Millipore) compared to measurement 
without filtration. Daughter ions m/z 904.3, 
748.3 and 417.1. 
 
 
 
 
 
 
 
 
Figure 3.9: Recovery of 50 pmol spiked BK1-9, 
BK1-8 and BK1-5 from serum after filtration with 
Nanosep®. Daughter ions m/z 904.3, 748.3 and 
417.1. 
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Figure 3.10: Iontrap calibration 
curves for BK1-9, BK1-8 and BK1-5 
on daughter ions m/z 904.3, 748.3, 
and 417.1, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Iontrap MS/MS spectra for (from the top) BK1-9 (m/z 530.9, 10 pmol on- column), 
BK1-8 (m/z 904.3, 2 pmol on-column) and BK1-5 (m/z 573.3, 2 pmol on-column). 
 
MERCATOR J Biomol Anal (2017) 1:1       18 
 
 
 
 
 
 
Figure 3.12: Development of targets for TOF-MRM using Synapt G2 Si MS. MS/MS isolation 
was performed for the triply-charged ion of BK, the doubly-charged ions of BK1-8 and BK1-7 
and the singly-charged ion of BK1-5.  
 
 
 
 
Figure 3.13: BK1-8 calibration for iKey Synapt MS (50-
500 fmol, 11 min gradient, m/z 452.74). Extracted ion 
chromatograms for m/z 642.3 and MS/MS spectra 
demonstrating excellent data quality across the 
concentration range. 
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Figure 3.14: BK1-9 degradation in control (n=3) and CRPS patient sera (n=12) measured with 
iontrap. MS/MS spectra (3 scans, intensities of fragment ions of BK1-9 m/z 904.3, BK1-8 m/z 
748.3, BK1-5 m/z 417.1. 
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Figure 3.15: Exemplary time course for BK (50 pmol) degradation 
in 2 µl control serum shown for BK1-8 (MS/MS m/z 452.74). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Schematic representation of Synapt data (5 controls, 
9 patients) for degradation of 50 pmol BK in 2 µl serum. 
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Results are shown in Figures 3.14 (iontrap), 3.15 and 3.16 (Synapt). While nanoLC-MS excelled 
in sensitivity and mass accuracy it suffered from a lack of tolerance to residual chemical matrix. 
We observed accumulation of material on the chromatographic column ultimately leading to 
clogging in-line frits and instrument shut-down. That was in part due to the unreliability of 
filtration units. Despite their use to create solutions devoid of molecules larger than 3 kDa, we 
on and off detected hemoglobin and albumin (67 kDa!) at large concentrations. This result 
explains the difficulties in the chromatographic separation, which was optimized for peptide 
separation, and  it prevented us from the acquisition of larger sample sets. We found that even 
more unfortunate as the methodology worked equally well with freshly drawn capillary blood 
from a finger tip and thus allowed us to determine local peptidase activity at the site of 
inflammation. 
Nevertheless, for the small sample set of 37 CRPS patients vs. seven healthy controls we 
learned, supported by the TLC-monitoring of BK products [38], that BK1-7 was transient while 
BK1-8 and BK1-5 provided reliable markers which were detectable after 1-2 min and leveled out 
at ~40-60 min [38, 45, 46]. The formation of lower BK1-5 levels in CRPS is in agreement with 
the hypothesis of reduced ACE-activity. However, the current patient cohort was both too small 
and too diverse to provide a clear picture. 
 
 
Conclusion 
 
LC-MS based analytical approaches shine for their sensitivity and specificity. Numerous 
methods have been developed worldwide for the detection of small and large components of 
biofluids and tissue. Methods which are established in clinical diagnostics use comparatively 
large amounts of biomaterial (e.g. 1 ml serum) and robust instrumentation although current 
research techniques can achieve detection limits in the pg or fmol range. While we have seen 
exceptional data for peptide detection from serum (high amol sensitivity) we also noted 
considerable interference by the chemical background. The reason for that is the reduced 
tolerance of nanoscale fluidic systems to solvent contamination and sample diversity. Therefore, 
we developed an alternative TLC-based approach for monitoring BK degradation by serum 
proteases [38]. The comparatively simple TLC method shone for its robustness and throughput 
and is currently further optimized for the measurement of capillary as well as venous blood.  
 
 
Acknowledgements 
 
Funding DFG KO1694/13-1 
 
 
References 
 
[1] Beerthuizen A, Stronks DL, Van`t Spijker A, Yaksh A, Hanraets BM, Klein J, Huygen FJ, 2012, 
Demographic and medical parameters in the development of complex regional pain syndrome type 1 
(CRPS1): Prospective study on 596 patients with a fracture. Pain 153:1187-1192.  
[2] Schmelz M, Petersen LJ, 2001, Neurogenic inflammation in human and rodent skin. News in 
Physiological Sciences 16:33-37. 
[3] Kaplan AP, Joseph K, Silverberg M, 2002, Pathways for bradykinin formation and inflammatory 
disease. Journal of Allergy and Clinical Immunology 109:195-209. 
MERCATOR J Biomol Anal (2017) 1:1       22 
 
 
 
 
 
[4] Blair SJ, Chinthagada M, Hoppenstehdt D, Kijowski R, Fareed J, 1998, Role of neuropeptides in 
pathogenesis of reflex sympathetic dystrophy. Acta Orthopaedica Belgica 64:448-451. 
[5] Taddei S, Bortolotto L, 2016, Unraveling the pivotal role of bradykinin in ACE inhibitor activity. 
American Journal of Cardiovascular Drugs 16:309-321. 
[6] de Mos M, Huygen FJPM, Stricker BHC, Dieleman JP, Sturkenboom MCJM, 2009, The association 
between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-
inflammatory pathogenesis of CRPS. Pain 142:218-224. 
[7] Schlereth T, Dittmar JO, Seewald B, Birklein F, 2006, Peripheral amplification of sweating -  a role for 
calcitonin gene-related peptide. The Journal of Physiology 576:823-832. 
[8] Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR, 2010, Resolvins RvE1 and RvD1 
attenuate inflammatory pain via central and peripheral actions. Nature Medicine 16:592-597. 
[9] Sommer C, Birklein F, 2010, Fighting off pain with resolvins. Nature Medicine 16(5):518-520. 
[10] König S, Schlereth T, Birklein F, 2017, Molecular signature for complex regional pain syndrome and 
its analysis. Expert Reviews in Proteomics, subm.  
[11] John H, Hierer J, Haas O, Forssmann W-G, 2007, Quantification of angiotensin-converting-enzyme-
mediated degradation of human chemerin 146-154 in plasma by matrix-assisted laser 
desorption/ionization-time-of flight mass spectrometry. Analytical Biochemistry 362(1):117-125. 
[12] Beneteau-Burnat B, Baudin B, 1991, Angiotensin-converting enzyme: Clinical applications and 
laboratory investigations on serum and other biological fluids. Critical Reviews in Clinical Laboratory 
Sciences 28(5-6):337-356. 
[13] Folch-Pi J, Lees M, Stanley GHS, 1957, A simple method for the isolation and  purification of total 
lipides from animal tissue. The Journal of Biological Chemistry 226:497-509. 
[14] Bligh EG, Dyer WJ,1959, A rapid method of total lipid extraction and purification. Canadian Journal of 
Biochemistry and Physiology 37:911-917. 
[15] Schlechtriem C, Fliedner A,Schäfers C, 2012, Determination of lipid content in fish samples from 
bioaccumulation studies: contributions to the revision of guideline OECD 305. Environmental Sciences 
Europe 24:13. 
[16] Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D, 2008, Lipid extration by methyl-
tert-butyl ether for high-throughput lipidomics. The Journal of Lipid Research 49:1137-1146. 
[17] Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, Serhan CN, Mayboroda OA,2012, 
Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of 
LC-MS/MS. Biochemica et Biophysica Acta 1821:1415-1424. 
[18] Aristoteli LP, Molloy MP, Baker MS, 2007, Evaluation of endogenous plasma peptide extraction 
methods for mass spectrometric biomarker discovery. Journal of Proteome Research 6(2):571-581. 
[19] Serhan CN, Chiang N, Van Dyke TE, 2008, Resolving inflammation: dual anti-inflammatory and pro-
resolution lipid mediators. Nature Reviews Immunology 8:349-361. 
[20] Hong S, Lu Y, Yang R, Gotlinger KH, Petasis NP, Serhan CN, 2007, Resolvin D1, protectin D1, and 
related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass 
spectrometry based on spectra and fragmentation mechanisms. Journal of the American Society for 
Mass Spectrometry 18(1):128-144.  
[21] Lu Y, Hong S, Yang R, Uddin J, Gotlinger KH, Petasis NA, Serhan CN, 2007, Identification of 
endogenous resolving E1 and other lipid mediators derived from eicosapentaenoic acid via 
electrospray low-energy tandem mass spectrometry: spectra and fragmentation mechanisms. Rapid 
Communications in Mass Spectrometry 21(1):7-22. 
[22] Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A, 2008, Simultaneous lipidomic analysis of 
three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty 
acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid 
Communications in Mass Spectrometry 22(2):75-83. 
[23] Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji R-R, 2010, Resolvins RvE1 and 
RvD1 attenuate inflammatory pain via central and peripheral actions. Nature Medicine 16(5):592-597. 
[24] Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, van Schacky C, Dechend R, 
Muller DN, Rothe M, Luft FC, Weylandt K, Schunck W-H, 2014, Dietary omega-3 fatty acid modulate 
the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. Journal of Lipid Research 
55:1150-1164. 
[25] Skarke C, Alamuddin N, Lawson JA, Li X, Fergusom JF, Reilly MP, FitzGerald GA, 2015, Bioactive 
products formed in humans from fish oils. Journal of Lipid Research 56:1808-1820. 
[26] Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN, 2014, Identification and signature profiles for 
pro-resolving and inflammatory lipid mediators in human tissue. American Journal of Physiology Cell 
Physiology 307:C39-C54. 
MERCATOR J Biomol Anal (2017) 1:1       23 
 
 
 
 
 
[27] Mas E, Barden A, Burke V, Beilin LJ, Watts GF, Huang R-C, Puddey IB, Irish AB, Mori TA, 2016, A 
randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. 
Clinical Nutrition 35(2):331-336. 
[28] Barden A, Mas E, Croft KD, Phillips M, Mori TA, 2014, Short-term n-3 fatty acid supplementation but 
not aspirin increases plasma proresolving mediators of inflammation. Journal of Lipid Research 
55:2401-2407. 
[29] Murphy RC, 2015, Specialized pro-resolving mediators: do they circulate in plasma? Journal of Lipid 
Research 56:1641-1642. 
[30] Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang TY, Tan PH, Gao YJ, Roy K, Corfas G, Lo EH, Ji RR, 
2008. Distinct roles of matrix metalloproteases in the early- and late-phase development of 
neuropathic pain. Nature Medicine 14(3):331-336. 
[31] Harper JI, Godwin H, Green A, Wilkes LE, Holden NJ, Moffatt M, Cookson WO, Layton G, Chandler 
S, 2010, A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel 
skin wash sampling assay for functional biomarker analysis. British Journal of Dermatilogy 132(2):397-
403. 
[32] Scholzen TE, König S, Fastrich M, Böhm M, Luger TA, 2007, Terminating the stress: peripheral 
peptidolysis of proopiomelanocortin-derived regulatory hormones by the dermal microvascular 
endothelial cell extracellular peptidases neprilysin and angiotensin.converting enzyme. Endocrinology 
148(6):2793-2805. 
[33] König S, Luger TA, Scholzen TE, 2006, Monitoring neuropeptide-specific proteases: processing oft 
he proopiomelanocortin peptides adrenocorticotropin and alpha-melanocyte-stimulating hormone in 
the skin. Experimental Dermatology 15(10):751-761. 
[34] Duncan MR, Lee JM, Warchol MP, 1995. Influence of surfactants upon protein/peptide adsorption to 
glass and polypropylene. International Journal of Pharmaceutics 120(2):179-188. 
[35] Cleugh J, Gaddum JH, 1963, The stability of purified preparations of substance P. Experientia 19:72-
73. 
[36] Higa T, Desiderio DM, 1988. Chemical degradation of 3H-labeled substance P in tris buffer solution. 
Analytical Biochemistry 173(2)463-468. 
[37] Suelter CH, DeLuca M, 1983, How to prevent losses of protein by adsorption to glass and plastic. 
Analytical Biochemistry 135(1):112-119. 
[38] Bayer M, Schildt A, Schlereth T, Birklein F, König S, 2016, Bradykinn degradation in CRPS. 
Proceedings Conferences on Biomolecular Analysis Münster, urn:nbn:de:hbz:6-83299734473:11. 
[39] Schmelz M, 2013. Local nociceptor sensitization with NGF: mechanical or heat hyperalgesia a la 
carte? European Journal of Pain 17(4):467-468. 
[40] Sheikh IA, Kaplan AP, 1989, Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in 
human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final 
degradation products. Biochemical Pharmacology 386:993-1000. 
[41] Dendorfer A, Wolfrum S, Wagemann M, Qadro F, Dominiak P, 2001, Pathways of bradykinin 
degradation in blood and plasma of normotensive and hypertensive rats. American Journal of 
Physiology 280(5):H2182-H2188. 
[42] Bhoola KD, Fiqueroa CD, Worthy K, 1992, Bioregulation of kinins: kallikreins, kininogens, and 
kininases. Pharmacological Reviews 44(1):1-80. 
[43] Kim KS, Kumar S, Simmons WH, Brown NJ, 2000, Inhibition of aminopeptidase P potentiates wheal 
response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. Journal of 
Pharmacology and Experimental Therapeutics 292(1):295-298. 
[44] Ji RR, Xu ZZ, Wang X, Lo EH, 2009, Matrix metalloprotease regulation of neuropathic pain. Trends in 
Pharmacological Science 30(7)336-340. 
[45] Schildt A, Schlereth T, Birklein F, König S, 2015, Complex regional pain syndrome: Targeted 
resolving and neuropeptide analysis. 48th DGMS, Wuppertal. 
[46] König S, 2016, Serum high-end biomarker analysis – Lipid and peptide detection in Multiple Sclerosis 
and Complex Regional Pain Syndrome. Plenary lecture 39th Symp Chromat Meth Invest Org 
Compounds, Szczyrk. 
 
 
 
